Krishnan Suma's Form 4 filing
Krystal Biotech, Inc. (KRYS) · filed Jul 11, 2025
- Accession no.
- 0001298711-25-000007
- Filed
- Jul 11, 2025
- Trade date
- Jul 9-10, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions. Open-market sales total $2.12M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Krishnan SumaCIK 0001298711 | Director, Officer (President, R&D), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 9, 2025 | Common Stock | SSaleDisposed | −200 | $150.14F2 | −$30,028 | 1,463,511 | Direct | Duplicate filing |
| Jul 10, 2025 | Common Stock | SSaleDisposed | −6,500 | $150.23F3 | −$976,495 | 1,457,011 | Direct | Duplicate filing |
| Jul 10, 2025 | Common Stock | SSaleDisposed | −300 | $151.39F4 | −$45,417 | 1,456,711 | Direct | Duplicate filing |
| Jul 9, 2025 | Common Stock | SSaleDisposed | −200 | $150.07F7 | −$30,014 | 1,532,856 | Indirect | Duplicate filing |
| Jul 10, 2025 | Common Stock | SSaleDisposed | −6,627 | $150.22F3 | −$995,507.94 | 1,526,229 | Indirect | Duplicate filing |
| Jul 10, 2025 | Common Stock | SSaleDisposed | −300 | $151.39F4 | −$45,417 | 1,525,929 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The transaction was executed in multiple trades ranging from $150.1200 to $150.1600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F3
The transaction was executed in multiple trades ranging from $150.0000 to $150.8500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 2 transactions in Table I.
- F4
The transaction was executed in three trades of 100 shares each at $151.350, $151.40, and $151.41, respectively. The price reported above reflects the average sale price.
Referenced by the price of 2 transactions in Table I.
- F7
The transaction was executed in two trades of 100 shares each at $150 and $150.14, respectively. The price reported above reflects the average sale price.
Referenced by the price of 1 transaction in Table I.